Citation | Devasthale, P; Wang, Y; Wang, W; Fevig, J; Feng, J; Wang, A; Harrity, T; Egan, D; Morgan, N; Cap, M; Fura, A; Klei, HE; Kish, K; Weigelt, C; Sun, L; Levesque, P; Moulin, F; Li, YX; Zahler, R; Kirby, MS; Hamann, LG Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem56:7343-57 (2013) [PubMed] Article |
---|
SMILES | COc1ccccc1-n1cc2[nH]c(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2c1=O |(35.12,-2,;35.89,-3.33,;35.13,-4.67,;33.59,-4.67,;32.82,-6.01,;33.61,-7.34,;35.15,-7.33,;35.9,-5.99,;37.44,-5.99,;38.34,-4.73,;39.82,-5.2,;41.15,-4.43,;42.48,-5.2,;43.81,-4.42,;42.49,-6.75,;43.82,-7.51,;45.16,-6.74,;41.16,-7.52,;41.15,-9.06,;39.82,-9.82,;39.81,-11.36,;41.14,-12.13,;41.14,-13.67,;42.48,-11.36,;42.48,-9.82,;43.81,-9.05,;39.83,-6.75,;38.36,-7.23,;37.89,-8.7,)| |